Oh. I was confused about the approval rejections. I see now the rejections are accomodating MSB. And anyway, as you have stated, the whole FDA attending MOA conferences is much better than Approving anything.
And I see all those failed primary end points were only there to allow secondary end points to shine on through.
I like your positivity. I bet you would say a gangrenous toe would be fabulous as there’s no need to cut your toenails.
Where is Novartis?, page-122
-
- There are more pages in this discussion • 1,395 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
93.5¢ |
Change
0.020(2.19%) |
Mkt cap ! $1.067B | |||
| Open | High | Low | Value | Volume |
| 92.0¢ | 94.5¢ | 92.0¢ | $1.622M | 1.742M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 64563 | 93.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.0¢ | 204239 | 3 |
View Market Depth
| Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |